Hypertriglyceridemia

Noncommunicable diseases like type 2 diabetes and cardiovascular disease cause more deaths worldwide than any other conditions, with a growing impact especially in low- and middle-income countries. Cardiovascular disease CVD is a leading cause of death globally, and its prevalence is rising despite awareness efforts. Diet and nutrition are important factors influencing these diseases, and this research explores the role of a traditional Chinese medicine nutritional drink in supporting cardiovascular health. The study evaluates the effects of the Perfect Heartio drink, a nutritional supplement made from diluted herbal extracts traditionally used in Chinese medicine. Participants will consume 15 grams of the drink twice daily for 12 weeks while their compliance is monitored. This intervention is being studied to assess its potential in improving heart and blood vessel function by measuring various cardiovascular health indicators. Participants will be assessed at the start and at weeks 4, 8, and 12 for lipid profiles, heart inflammation, heart injury, and heart remodeling. Quality of life and self-perceived health status will also be evaluated over these timepoints. The study includes healthy adults aged 18 and above who agree to follow the intervention plan and attend follow-up visits. Monitoring throughout the study will help researchers understand the drinks impact on cardiovascular health markers over the 12-week period.

Researchers are evaluating an AI-assisted digital health tool called the Smart family doctor to improve control of hypertension, diabetes, and dyslipidemia in adults who have undergone coronary artery bypass grafting CABG or percutaneous coronary intervention PCI. This study uses a randomized controlled design involving about 536 participants across 5-10 hospitals. Participants must be adults aged 18 or older with a history of CABG or PCI and the specified conditions. Participants in the experimental group will use the AI-assisted Smart family doctor app that provides personalized health education, targeted guidance on managing blood pressure, blood sugar, medication adherence, exercise, and smoking cessation. They will also receive tailored reminders and can report self-measured health data for feedback. Both groups receive weekly 3-hour health management guidance from health managers, and participants will wear a smart band daily for health data collection during the 6-month study period. Throughout the study, participants will be assessed for control rates of hypertension, diabetes, and hyperlipidemia at 6 months. Additional measures include blood pressure, cholesterol levels, blood glucose, physical activity, quality of life, psychological status, and cognitive function. The study monitors health data continuously via smart bands and collects self-reports and clinical assessments to evaluate the interventions impact over the 6 months.

Researchers are evaluating the effects of Diaberine, a berberine-based nutraceutical, on blood sugar regulation and metabolism in adults with metabolism disorder. This randomized, triple-blind, placebo-controlled trial will study 80 participants aged 18 to 70 over 24 weeks to assess how well this dietary supplement may aid in these health areas. Participants will be randomly assigned to one of two groups. One group will take Diaberine capsules containing Vitamin B12, berberine, magnesium citrate, cinnamon bark extract, chromium, and other ingredients three times daily, 15 minutes before meals. The other group will take placebo capsules with similar appearance but without the active ingredients. Both treatments will continue for 24 weeks with regular monitoring. During the study, participants will have their blood sugar regulation and metabolism measured at baseline, week 12, and week 24. Additionally, quality of life and weight changes will be tracked at multiple points throughout the 24 weeks. Participants will be monitored through questionnaires, blood tests, and weight assessments to evaluate the supplements effects and tolerance over time.

Researchers are studying the effects of MAR001 on adults with high triglycerides and remnant cholesterol. This phase 2, randomized, double-blind, placebo-controlled trial aims to compare MAR001 with a placebo to see how it changes triglyceride levels after eating a mixed meal. The study focuses on the postprandial after eating state in adults aged 18 to 75 years with elevated triglycerides and remnant cholesterol. Participants receive either MAR001 or a matching placebo through subcutaneous injections. The treatment period lasts 12 weeks, during which researchers measure changes in triglycerides and remnant cholesterol levels after a mixed meal. The study uses a quadruple-blind design, meaning participants, care providers, investigators, and outcomes assessors do not know who receives MAR001 or placebo. During the study, participants will have fasting triglyceride tests at screening and regular assessments throughout the 12 weeks. Researchers will track the area under the curve and peak plasma concentrations of triglycerides and remnant cholesterol after meals to evaluate treatment effects. Participants must maintain stable diets and medication regimens during the trial. Safety and adherence will be monitored with ongoing assessments to understand the impact of MAR001 compared to placebo.

Researchers are evaluating the safety and tolerability of multiple subcutaneous injections of JMT202 in Chinese adults with hypertriglyceridemia. This study is a Phase 1b2a randomized, double-blind, placebo-controlled trial aimed at assessing how participants respond to this investigational treatment, including its effects on triglyceride levels and overall health markers. Participants will receive either JMT202 injections or placebo injections according to the study protocol. The study involves multiple doses administered under medical supervision. Some participants in each dose group will also undergo MRI-PDFF scans to assess fat content. Throughout the trial, participants are expected to maintain their usual diet and exercise habits while avoiding alcohol and strenuous exercise before visits. During the study, participants will undergo regular safety assessments including monitoring for treatment-emergent adverse events, vital signs, physical exams, laboratory tests, electrocardiograms, and injection site reactions from Day 1 to Day 99. The trial period includes careful observation of health changes and adherence to stable lipid-lowering treatments. The total duration of participant involvement spans from screening through approximately three months of follow-up after treatment begins.

Researchers are evaluating the appropriate dosage of HRS-1301 in adults with dyslipidemia, a condition involving abnormal lipid levels in the blood. This phase II trial aims to assess both the effectiveness and safety of HRS-1301 after 12 weeks of treatment. The study is led by Shandong Suncadia Medicine Co., Ltd. and involves participants with varying degrees of cardiovascular risk and cholesterol levels. Participants will be randomly assigned to one of several groups receiving different oral doses of HRS-1301 or a placebo. The study is double-blind and placebo-controlled, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. Treatment lasts 12 weeks, with doses ranging across multiple groups to determine the most suitable amount. During the trial, participants will have their cholesterol levels and related markers regularly monitored to measure changes from baseline. The primary outcome focuses on the percentage change in LDL cholesterol after 12 weeks. Secondary outcomes include changes in total cholesterol, HDL, triglycerides, other lipid markers, and inflammation levels. Safety will be monitored by recording adverse events over approximately six months. Participants will attend scheduled visits for assessments throughout the study.

Researchers are studying CTX310, a new gene-editing treatment, in adults aged 18 to 75 with dyslipidemias that do not respond to current therapies. This early-phase, open-label trial aims to evaluate the safety and tolerability of CTX310, a lipid nanoparticle formulation designed to edit the ANGPTL3 gene involved in lipid regulation. Participants will receive a single intravenous infusion of CTX310. The study is conducted across multiple centers and follows an ascending dose design to assess safety at different dose levels. The treatment period includes monitoring for up to 12 months after infusion to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary effects on lipid levels. During the study, participants will have regular assessments including laboratory tests to monitor lipid levels and organ function, safety evaluations, and pharmacological measurements. Researchers will track adverse events and treatment effects for up to one year following the infusion. Participants must adhere to study visits and contraception requirements during this time to ensure accurate monitoring and safety.

Researchers are evaluating how the body processes HRS-1301 tablets in adults with different levels of kidney function compared to healthy adults. The goal is to understand how kidney impairment affects the medicines behavior in the body and to develop dosing recommendations for patients with kidney problems. This is a phase 1 clinical trial sponsored by Shandong Suncadia Medicine Co., Ltd. Participants will receive a single oral dose of HRS-1301 tablets. The study includes groups with mild, moderate, and severe kidney impairment as well as healthy subjects. The trial is open-label, meaning both researchers and participants know the treatment being given. The treatment period lasts up to 8 days post-dose to observe the drugs effects. During the study, participants will undergo blood and urine tests to measure drug levels and how the body clears the medicine over time. Researchers will track maximum drug concentration, exposure over time, elimination half-life, and safety through adverse event monitoring. These assessments occur from dosing up to 8 days later. The total participation duration varies but includes close monitoring of drug behavior and safety.

Researchers are studying the effects of SHR-1918 in adults with hypertriglyceridemia, a condition characterized by high levels of triglycerides in the blood. This Phase III clinical trial aims to assess both the efficacy and safety of SHR-1918 compared to a placebo. The study is randomized, double-blind, and placebo-controlled to ensure reliable results. The lead sponsor for this research is Beijing Suncadia Pharmaceuticals Co., Ltd. Participants will receive subcutaneous injections of SHR-1918 or a placebo in two different doses. The treatment will last for up to 48 weeks, with evaluations at 24 and 48 weeks to measure changes in serum triglyceride levels and other lipid markers. The study has two experimental groups receiving different doses of SHR-1918 or placebo, and participants are randomly assigned to these groups. During the study, participants will undergo regular assessments including blood tests to monitor triglycerides, LDL cholesterol, HDL cholesterol, and other lipid-related measures. Researchers will also track the proportion of participants reaching target triglyceride levels and monitor any adverse events or injection site reactions. The primary outcome is the percentage change in triglyceride levels at weeks 20 and 24. The total participation duration may last about one year, including safety monitoring and follow-up evaluations.

Researchers are evaluating the safety and effectiveness of solbinsiran compared to a placebo in adults with severe hypertriglyceridemia, a condition involving very high triglyceride levels. This Phase 2, randomized, double-blind, placebo-controlled study aims to understand how solbinsiran affects triglycerides and other lipid measures. The study focuses on participants with fasting triglyceride levels of 500 mgdL or higher. Participants will be randomly assigned to receive either solbinsiran or a placebo through two subcutaneous injections. The study uses a parallel design, meaning participants receive only one of the two treatments. The trial will last at least 24 weeks, with assessments occurring from baseline through weeks 16 to 24 to measure changes in triglycerides and other lipids. During the study, participants will undergo evaluations of lipid levels including triglycerides, Angiopoietin-like-3, very-low-density lipoprotein cholesterol, and non-high-density lipoprotein cholesterol. Pharmacokinetic assessments will be done to measure the drug concentration over time. Safety and efficacy will be monitored throughout the trial, which is expected to complete in August 2027.